Abstract:e17605 Background: Platinum-based neoadjuvant chemotherapy (NACT) plus interval debulking surgery (IDS) and adjuvant chemotherapy has been an established alternative for advanced epithelial ovarian cancer (EOC). The chemotherapy response score (CRS) has been applied to assess the efficacy of NACT in high-grade serous ovarian cancer (HGSOC). The purpose of this study was to assess the effect of NACT on tumor immune microenvironment (TIME) of HGSOC, and the correlation between the TIME and CRS. Methods: All patients underwent NACT with IDS. Formalin-fixed paraffin-embedded tissue samples were collected from pretreatment biopsy specimens and the corresponding post-NACT surgical specimens. The densities and percentage of various cell populations within the TIME were analyzed by multiplex immunohistochemistry (3DMedcines Inc.), including specific tumor infiltrating lymphocytes (TILs) (CD8 + T cell, FOXP3 + CD4 + Treg cell and CD20 + B cell), tumor associated macrophages (TAMs), NK cells (CD56 dim and CD56 bright). Patients were divided into three groups according to CRS based on pathological reaction of surgical specimens: CRS1 shows no or minimal response, CRS2 shows moderate response and CRS3 usually shows complete or near-complete response. Statistical analyses were performed using GraphPad Prism 7.0. P < 0.05 was considered statistically significant. Results: A total of 25 HGSOC patients were enrolled in this study, 32% (8/25) of patients with CRS 1, 64% (16/25) with CRS 2, and 4% (1/25) with CRS 3. After NACT, patients with CRS 2 or 3 had a significant increase of the densities of CD20 + B cells in stroma (pre-NACT 15.71/mm 3 vs. post-NACT 87.82/mm 3 , p = 0.048). We also observed borderline significant increases of percentage of CD20 + B cells, the densities and percentage of CD8 + T cells in stroma after NACT (pre-NACT vs. post-NACT, 0.32% vs.1.54%, 56.35/mm 3 vs. 311.35/mm 3 , 0.95% vs. 5.48%, respectively). Meanwhile, no significant change in CD4 + T, TAMs and NK cells. In patients with CRS 1, we observed a significant increase of the densities and percentage of CD4 + FOXP3 + Treg in stroma (pre-NACT vs. post-NACT, 1.38/mm 3 vs. 19.75/mm 3 , p = 0.01; 0.04% vs. 0.41%, p = 0.017, respectively), while CD8 + T, CD20 + B, TAMs and NK cells did not change significantly. Additionally, we found a significant difference in CD56 bright NK infiltration when comparing CRS 2 or 3 group with CRS1 group in post-NACT (0.5/mm 3 vs.12/mm 3 , p = 0.049; 0.005% vs. 0.23%, p = 0.048). Conclusions: These data suggest immune infiltrate in TIME may serve as a biomarker to predict response to NACT in HGSOC. The infiltration of CD8+ T and CD20+ B cell was more pronounced in CRS2 or 3, while the enhanced infiltration of FOXP3 + CD4 + Treg cells is associated with immunosuppressive TIME and poor response (CRS1). The mechanism of lymphocyte regulation is not completely understood, thereby deserving further investigation.

Neoadjuvant chemotherapy for high-grade serous ovarian cancer: radiologic–pathologic correlation of response assessment and predictors of progression

The Impact of Neoadjuvant Chemotherapy on the Tumor Microenvironment in Advanced High-Grade Serous Carcinoma

Prognostic value of complete metabolic response on ¹⁸F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer

Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer

What Influences the Long-Term Survival of Advanced High-Grade Serous Ovarian Cancer?

Predictive impact of clinical factors on chemosensitivity in advanced high-grade serous ovarian carcinoma according to chemotherapy response score

Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies

The tumor immune microenvironment correlates with neoadjuvant chemotherapy response in high-grade serous ovarian cancer.

In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy

Image analysis Uncovers associations between immune landscape, collagen structure, and neoadjuvant chemotherapy in high-grade serous ovarian carcinomas

The association of the chemotherapy response score and homologous recombination deficiency in patients undergoing interval tumor reductive surgery following neoadjuvant chemotherapy

Prognostic Predictive Value of Preoperative Intratumoral 2-Deoxy-2-(18f)fluoro-d-glucose Uptake Heterogeneity in Patients with High-Grade Serous Ovarian Cancer

Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer

Radiographic response to neoadjuvant therapy and its impact on scope of surgery and prognosis in stage IIB/III soft tissue sarcomas

Predictive value of tumor microenvironment on pathologic response to neoadjuvant chemotherapy in patients with undifferentiated pleomorphic sarcomas

Preoperative Omental Metastasis-Related Maximum Standardized Fluorine-18-fluorodeoxyglucose Uptake Value Can Predict Chemosensitivity and Recurrence in Advanced High-Grade Serous Ovarian Cancer Patients

Are baseline ultrasound and mammographic features associated with rates of pathological completes response in patients receiving neoadjuvant chemotherapy for breast cancer?

Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models

Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study

Utility of a Chemo-Response Pathologic Score to Predict Outcomes in Patients Undergoing Neoadjuvant Chemotherapy for Advanced Ovarian Cancer

Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis